Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Gastro Other
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Gastro Other
    Endoscopic Ultrasound-Fine Needle Aspiration Feasible, Safe for Children - (DGNews)
    Endoscopic Ultrasound-Fine Needle Aspiration Predicts 5-year Survival in Pancreatic Endocrine Tumours - (DGNews)
    Study Finds Prevalence of Barrett's Oesophagus in Asymptomatic Women - (DGNews)
    Benefits of Bariatric Surgery in Adolescents Persist After 2 Years: Presented at AHA - (DGDispatch)
    Lubiprostone Approved in Switzerland for Chronic Idiopathic Constipation - (DGNews)

    News archive

     Recent webcasts/CME - Gastro Other
    • Modifying Treatment, Maximizing Benefit: A Case-Based Exploration of Advanced CRC Management
    • Applying Evidence to Improve Outcomes in Mild-to-Moderate Ulcerative Colitis: A Roundtable Discussion
    • Goals of Therapy for Mild-to-Moderate Ulcerative Colitis: What is Achievable?
    • Opioid Induced Constipation in Palliative Care : Consideration in the Care of a Unique Population
      Carcinoid Tumors of the Gastrointestinal Tract

      Webcasts/CME archive

       Recent cases - Gastro Other
        Lipemic Serum In Hyperlipidemic Pancreatitis
        Yellow-White Lesions in the Upper Gastrointestinal Tract
        Transient Anti-GAD Antibody Positivity and Acute Pancreatitis with Pancreas Tail Swelling in a Patient with Susceptible Haplotype for Type 1 Diabetes Mellitus
        Pancreatic Injury Successfully Treated with Endoscopic Stenting for Major Pancreatic Duct Disruption
        Jejuno-Jejunal Invagination Caused by Epithelioid Sarcoma: A Case Report

        Cases archive
          




        my personal edition > gastro other > news
        divider

          E-Mail this DGDispatch to a colleague

        DGDispatch


        P. Amarus Derivative May Help Prevent Progression of Hepatitis B to Chronic State: Presented at ACG

        By Paula Moyer

        Honolulu, HI -- November 8, 2005 -- Patients with hepatitis B who took the herbal treatment Phyllanthus amarus (Hepavirin) in a placebo-controlled study had a greater level of viral clearance than placebo subjects, according to investigators who presented their findings here at the 70th annual meeting of the American College of Gastroenterology (ACG).

        "This treatment results in significantly faster clearing of antigens and normalization of liver enzymes than placebo in acute hepatitis B," said principal investigator Sarabjeet Singh, MD, Consultant Hepatologist, L.L.R.M. Medical College, Meerut, Uttar Pradesh, India, in a presentation on November 2nd.

        The researchers were interested in the potential of P. amarus for the treatment of hepatitis B because of the cost of ongoing treatment with chronic disease, a particular concern with patients who are immune compromised and those who acquire the disease perinatally.

        Dr. Singh and colleagues assessed the natural course of the disease in the initial 4 weeks and assessed the impact of P. amarus on the infection and on hepatic functions up to 24 weeks.

        The 200 study subjects had serologically proven acute hepatitis B. They were randomized equally to receive either treatment or placebo. The researchers obtained the patients' medical histories, conducted physical examinations, and laboratory assessments, including hemoglobin, serum lipids, erythrosedimentation rate, and platelet counts.

        Laboratory tests also focused on several hepatitis-specific laboratory values, such as serum bilirubin, serum alanine aminotransferase (ALT), aspartate aminotransferase (AST), and serum proteins, as well as hepatitis B-specific values such as hepatitis B surface antigen (HBSAg), hepatitis B e-antigen (HBeAg), and immunoglobulin M anti-hepatitis B core antibodies.

        Subjects received one 500-mg tablet of P. amarus or placebo three times daily. The treatment period was 4 weeks; the investigators recorded the patients' laboratory values and clinical findings at baseline and at 16 and 24 weeks.

        By the end of the follow-up period, 82% of patients in the treatment group and 80% in the placebo group remained in the trial.

        Patients on the study drug experienced a more rapid improvement of symptoms and normalization of ALT and AST values than did those on placebo, according to Dr. Singh.

        In addition, 96.3% of patients on P. amarus showed a clearing of HBsAg, compared to 81.2% of patients on placebo (P < .001). HBeAg clearing occurred in 96.3% of the patients on the study drug compared to 88.7% of the patients on placebo (P < .001).

        Eight patients in the placebo group had elevated liver enzymes, compared to none on the study drug.


        [Presentation title: A Placebo-controlled Double-blind Clinical Trial of the Efficacy of Hepavirin in Viral Hepatitis B. Abstract 658]



        E-Mail this DGDispatch to a colleague   To print, use this version






        All contents Copyright (c) 1995-2009 Doctor's Guide Publishing Limited. All rights reserved.



        The NTK initiative. Physicians helping physicians identify Need-To-Know science
           Feedback
        Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
        Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
        1
        2
        3
        4
        5
        6
        7
        Send